ERNEST GRAYPEL: Open Payments
NPI 1265723407 · ST LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,087 in 100 payments from 17 companies in 2025. Trend: 2023 $1,530 · 2024 $1,972 · 2025 $2,087
Food & beverage: $2,087
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 20 | $451 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $403 |
| Alkermes, Inc. | 10 | $226 |
| Alpha Cognition USA, Inc. | 6 | $190 |
| Axsome Therapeutics, Inc. | 9 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $149 |
| Otsuka America Pharmaceutical, Inc. | 8 | $137 |
| Vanda Pharmaceuticals Inc. | 4 | $99 |
| Neos Therapeutics, LP | 3 | $55 |
| Almatica Pharma LLC | 3 | $50 |
Products named: INGREZZA, CAPLYTA, ARISTADA, Zunveyl, REXULTI, Auvelity, TRINTELLIX, FANAPT.
Industry payments across MO — which companies pay providers there.
